Study Summary
Primary Objective: To determine the safety and maximum tolerated dose of intravenous infusions of escalating doses of CD7 negative T-cells expressing CD7-CARs (CD7-CAR T cells) in pediatric patients with recurrent/refractory CD7+ hematological malignancies after lymphodepleting chemotherapy. Secondary Objectives: To evaluate the antileukemic activity of CD7-CAR T cells. As a phase I study, efficacy is not the primary objective of this study, but remains an important outcome to evaluate. We will determine the anti-leukemic activity of the CD7-CAR T cells in the bone marrow and in the treatment of extramedullary disease.
Interested in this trial?
Submit an InquiryInterventions
FludarabineDRUG
Day 4, 3, 2 at 40 mg/m2 dose. Intravenous.
CyclophosphamideDRUG
Day -2 at 90mg/m2 dose. Intravenous infusion.
CliniMACSDEVICE
CD7-CAR T-cell infusion
MesnaDRUG
Given intravenously divided as 4 doses equal to 25% cyclophosphamide dose per dose of Mesna administered prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| St. Jude Children's Research Hospital | Memphis | Tennessee | United States |